Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Category: #health  By Mateen Dalal  Date: 2020-02-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial

A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have bagged a USD 10 million development milestone payment under its worldwide licensing agreement with the leading biopharmaceutical company, Merck & CO., for the initiation of a Phase 2 clinical trial of an anti-CD27 agonist, MK-5890, in NSCLC (non-small cell lung cancer).

For the record, Aduro Biotech is focused on developing therapies targeting the STING (Stimulator of Interferon Genes) and APRIL (A Proliferation Inducing Ligand) pathways for the treatment of autoimmune, inflammatory diseases and cancer.

In preclinical studies, Adoro’s anti-CD27 antibody activation has demonstrated enhanced T-cell response, which in combination with immune checkpoint inhibition has shown the ability to achieve complete tumor eradication. 

Andrea van Elsas, Chief Scientific Officer at Aduro was reportedly quoted saying that the company is elated to witness Merck & CO putting efforts to advance MK-5890 through development with the initiation of a Phase 2 clinical trial in non-small cell lung cancer.

Elsas added saying that the achievement of the recent milestone would not have been possible without the progressive efforts of the exceptional team at Aduro Biotech Europe and the B-select technology,  which have produced various monoclonal antibodies, along with an anti-APRIL antibody, BION-1301 and MK-5890 that the company is currently developing for Berger's disease (IgA nephropathy).

As per sources close to the matter, the Phase 2 clinical trial is designed to assess the safety  and efficacy of pembrolizumab in combination with an anti-CD27 agonist, MK-5890 in patients suffering from advanced non-squamous or squamous NSCLC, that have been treated earlier with anti-PD-L1 therapy. The study is 1 of the 3 pembrolizumab sub-studies that were supposed to be conducted under one pembrolizumab umbrella master protocol.

Source Credit: https://investors.aduro.com/news-releases/news-release-details/aduro-biotech-announces-milestone-achieved-under-merck?field_nir_news_date_value%5bmin%5d=

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Saudi Arabia aims for net-zero carbon emissions by the year 2060
Saudi Arabia aims for net-zero carbon emissions by the year 2060
By Mateen Dalal

Global oil producer, Saudi Arabia has recently stated that it intends to reach zero greenhouse gas emission levels by 2060, thereby joining the bandwagon with other 100 countries towards limiting the impact of climate change. Although the kingdom pl...

Abbott unites with Real Madrid to aid child welfare worldwide
Abbott unites with Real Madrid to aid child welfare worldwide
By Mateen Dalal

Abbott’s partnership with Real Madrid will cater to children’s education, social welfare, sports activities in around 80 countries It will also provide health and nutritional assistance to Academy teams and product development and inn...

TotalEnergies commences its UK Offshore Wind Hub in Scotland
TotalEnergies commences its UK Offshore Wind Hub in Scotland
By Mateen Dalal

French oil and gas major, TotalEnergies SE has inaugurated its UK Offshore Wind Hub in Scotland which will be part of the company's existing offshore operations center in Aberdeen and allow employees to shift from oil and gas to offshore win...